Daridorexant
Cross-source consensus on Daridorexant from 1 sources and 4 claims.
1 sources · 4 claims
How it works
Benefits
Dosage & preparation
Evidence quality
Highlighted claims
- Daridorexant blocks orexin 1 and orexin 2 receptors to inhibit the wake-promoting orexin pathway. — Daridorexant in children and adolescents with insomnia disorder: study protocol for a multicentre randomised controlled trial
- Daridorexant is being studied as the first controlled paediatric trial of a DORA in children and adolescents with insomnia disorder. — Daridorexant in children and adolescents with insomnia disorder: study protocol for a multicentre randomised controlled trial
- Daridorexant is approved for adult insomnia at 25 mg and 50 mg in multiple jurisdictions. — Daridorexant in children and adolescents with insomnia disorder: study protocol for a multicentre randomised controlled trial
- Daridorexant has adult insomnia efficacy and is considered safe in adults aged 18 years and older. — Daridorexant in children and adolescents with insomnia disorder: study protocol for a multicentre randomised controlled trial